These findings provide a strong rationale for therapeutic strategies aimed at modulating T-cell metabolism—either through direct pharmacologic activation of AMPK or inhibition of mTORC1—to enhance the metabolic fitness and memory potential of tumor-reactive T cells. This evidence concerns the gene PRKAA1 and neoplasm.